ArticleScientific reports2026
Studying the expression levels of LncRNA-MEG3 and miR-147b in the serum of psoriasis patients with and without dyslipidemia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic systemic inflammatory skin disorder that is strongly associated with metabolic disorders, including obesity, insulin resistance, hypertension, and dyslipidemia. Dyslipidemia causes abnormalities in lipid profiles, such as elevated triglycerides or low density lipoprotein (LDL) levels. Measure maternally expressed gene 3 (MEG3) and microRNA-147b in serum of patients with and without dyslipidemia compared to healthy control. These measurements were compared with clinical characteristics, clinical parameters, and laboratory investigations. Serum expression levels of MEG3 and microRNA-147b, as non-coding RNA biomarkers, were measured across four equally subcategorized groups (patients with and without dyslipidemia (N = 66) and healthy controls with and without dyslipidemia (N = 66) using Polymerase Chain Reaction (PCR). Psoriatic patients exhibited a high significantly body mass index and elevated low-density lipoprotein levels compared with controls (p = 0.038,0.010) respectively, while fasting blood glucose was significantl at p = 0.001. Fasting blood glucose and lipid parameters showed low levels in patients without dyslipidemia and high levels of high-density lipoprotein than those with dyslipidemia. Expression Level of MEG3 was significantly downregulated, whereas microRNA-147b was markedly upregulated in psoriatic patients (p < 0.0001). MEG3 expression was negatively correlated with disease severity indices and lipid levels and inversely correlated with microRNA-147b, which also negatively correlated with disease duration. MEG3 and miR-147b, as non-coding RNAs, may show differential expression among psoriasis patient subgroups and could be associated with disease-related parameters, but their value as markers of disease severity or prognosis remains to be confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.